Samsung Biologics Decides to Acquire Swiss Peptide CDMO PolyPeptide Group AG for 2.7 Trillion Won via Public Tender Offer
Samsung Biologics has decided to acquire 33,016,411 shares of PolyPeptide Group AG, a Swiss-listed peptide CDMO company, for approximately 2.7 trillion won via a public tender offer, representing 100% of the target's outstanding shares. The largest shareholder Draupnir Holding B.V. has committed to tender its entire 55.65% stake, increasing the likelihood of deal completion.
The acquisition will be partially financed through debt, and the tender is conditional on a minimum tender of 66.7% of the fully diluted shares. If this condition is not met, the transaction may not proceed.
PolyPeptide Group AG has recorded net losses for three consecutive years, with recent annual revenue of about 670 billion won. Samsung Biologics aims to strengthen its peptide CDMO capabilities and enter the next-generation biopharmaceutical market through this acquisition.
The expected closing date is November 30, 2026, subject to regulatory approvals including merger clearance and foreign investment authorization. Any material changes will be disclosed through subsequent filings.
[AI Summary]Samsung Biologics' acquisition of PolyPeptide Group is a strategic investment to secure long-term growth, with the focus on preempting the peptide market despite the target's ongoing losses. The conditional tender structure and financing plans are key risk factors; the impact on Samsung C&T's stock is neutral, hinging on deal closure and post-merger integration.
KOSPI Filing Information
Decision on Acquisition of Stocks and Investment Certificates of Other Corporations (Major Management Matters of Subsidiary)